Promoter Antigen Through Down-Modulation of Its the Melanocyte Lineage MelanA / MART-1 Diminishes Expression of the Gene Encoding Lines Produce a Soluble Protein That from Immune Recognition : Melanoma Cell

[1]  S. Tóth,et al.  Autocrine and paracrine regulation by cytokines and growth factors in melanoma. , 2000, Cytokine.

[2]  F. Marincola,et al.  Heterogeneity in expression of human leukocyte antigens and melanoma‐associated antigens in advanced melanoma , 2000, Journal of cellular physiology.

[3]  S. Pervaiz,et al.  Melanoma antigen recognition by tumour‐infiltrating T lymphocytes (TIL): effect of differential expression of Melan‐A/MART‐1 , 2000, Clinical and experimental immunology.

[4]  S. Steinberg,et al.  Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. , 1999, Journal of immunology.

[5]  F. Garrido,et al.  Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors , 1999, International journal of cancer.

[6]  F. Marincola,et al.  Selective Histocompatibility Leukocyte Antigen (Hla)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624mel28 Melanoma Cells , 1999, The Journal of experimental medicine.

[7]  M. Toda,et al.  Frequency of clonally expanded T cells evaluated by PCR from a single cell. , 1999, Journal of immunological methods.

[8]  D. Levy,et al.  Proto-oncogene PML controls genes devoted to MHC class I antigen presentation , 1998, Nature.

[9]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[10]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[11]  S. Steinberg,et al.  Heterogeneous expression of melanoma‐associated antigens and HLA‐A2 in metastatic melanoma in vivo , 1998, International journal of cancer.

[12]  J. Zeuthen,et al.  In vivo and in vitro generation of a new altered HLA phenotype in melanoma‐tumour‐cell variants expressing a single HLA‐class‐I allele , 1998, International journal of cancer.

[13]  T. Boon,et al.  Tumor antigens recognized by T lymphocytes , 1997, International journal of clinical & laboratory research.

[14]  T. Kageshita,et al.  Differential Expression of MART‐1 in Primary and Metastatic Melanoma Lesions , 1997, Journal of immunotherapy.

[15]  T. Wobbes,et al.  Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. , 1997, Cancer research.

[16]  L. Butterfield,et al.  Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions. , 1997, Gene.

[17]  L. Wilson,et al.  Antigen processing and presentation by human trophoblast-derived cell lines. , 1997, Journal of immunology.

[18]  F. Oesch,et al.  Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.

[19]  P. J. van den Elsen,et al.  In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[21]  H. Eisen,et al.  Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self' sequences: autoimmune nature of the anti-melanoma CTL response. , 1997, International immunology.

[22]  B. Dréno,et al.  Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. , 1997, Journal of immunology.

[23]  D. Cole,et al.  Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. , 1996, Seminars in oncology.

[24]  J. Bryant,et al.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. , 1996, The Journal of clinical investigation.

[25]  Yao-Tseng Chen,et al.  Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Buzaid,et al.  lnterleukin-6 production and secretion in human melanoma cell lines: regulation by interleukin-1 , 1996, Melanoma research.

[27]  F. Jotereau,et al.  Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions , 1996, The Journal of experimental medicine.

[28]  F. Marincola,et al.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.

[29]  S. Rosenberg,et al.  Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. , 1996, Journal of immunology.

[30]  A. Amoroso,et al.  Peptide‐specific ctl in tumor‐infiltrating lymphocytes from metastatic melanomas expressing mart‐1/melan‐a, gp100 and tyrosinase genes: A study in an unselected group of hla‐a2.1‐positive patients , 1995, International journal of cancer.

[31]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[32]  R. Kerbel,et al.  Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not coregulated. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[33]  A Sette,et al.  Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. , 1995, Journal of immunology.

[34]  S. Rosenberg,et al.  Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. , 1995, Journal of immunology.

[35]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  K. Sakaguchi,et al.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[37]  M. Herlyn,et al.  Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes , 1994, International journal of cancer.

[38]  D. Guerry,et al.  Production of multiple cytokines by cultured human melanomas * , 1993, Experimental dermatology.

[39]  T. Luger,et al.  Heterogeneity of cytokine production by human malignant melanoma cells , 1992, Experimental dermatology.

[40]  N. Barth,et al.  Continuous interleukin‐2 and tumor‐infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial , 1991, Cancer.

[41]  K. Isselbacher,et al.  Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. , 1991, Cancer research.

[42]  A. Davidson.  Tumor infiltrating lymphocytes. , 1990, Journal of the National Medical Association.

[43]  S. Dubinett,et al.  TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER , 1989, The Lancet.

[44]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[45]  Yao-Tseng Chen,et al.  T311--an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. , 2000, Pathology, research and practice.

[46]  F. Marincola,et al.  Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. , 1998, Critical reviews in immunology.

[47]  S. Rosenberg,et al.  Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. , 1997, International reviews of immunology.

[48]  F. Marincola,et al.  Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. , 1997, The cancer journal from Scientific American.

[49]  M. Mihm,et al.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[50]  R. Radinsky,et al.  Heterogeneity of cytokine and growth factor gene expression in human melanoma cells with different metastatic potentials. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.